Dublin, July 13, 2017 (GLOBE NEWSWIRE) -- The "Antibiotics: the Quest for New Super Drugs: Technologies, Markets, Competitors and Opportunities: 2017-2022 Analysis and Forecasts" report has been added to Research and Markets' offering. Antibiotics are drugs used to treat infections that are caused by bacteria. The introduction of antibiotics is recognized as one of the most transformative events in medicine. Prior to the introduction of the first antibiotics in the 1930s and 1940s, bacterial infections were often fatal, and invasive surgery was accompanied by a high risk of infectious complications. Today, antibiotics are used routinely to treat and prevent infection. However, drug- and multi-drug-resistant bacterial strains pose a serious threat in the clinical setting as they directly contribute to an increase in morbidity and mortality, as compared to the underlying disease itself. Due to antibiotic resistance, new antibiotic super drugs are desperately needed to fight infections like MRSA, CRE, ESBLs and C. difficile. And that is beyond dealing with diseases like drug-resistant Gonorrhea, which affects an estimated 78 million people globally, or TB, which affects 10 million people worldwide, or even the 1 million+ people in the U.S. who get hospitalized with Pneumonia annually. Or bioweapons like Anthrax. Unfortunately, it is hard to discover new antibiotics. Further compounding the problem, from approximately 20 traditional pharmaceutical companies investing in antibiotic research in the 1980s, there are now only five with significant active internal research programs. As a result, most novel antibiotic development is now being conducted by small biotech companies.
Over the last few years there has been a growing realization among the various stakeholders (Industry players, governments, authorities and medical charities) that something needs to be done to address the issues impacting antibiotic R&D, and avoid the looming socio-economic burden of antimicrobial resistance.
Current antibiotics work now, for the most part. But if an epidemic of one of the multi-drug-resistant strains rapidly spreading across the globe happens, it will be too late to start funding the discovery of new antibiotics. The need to invest is now, so there are options when the inevitable next black death appears. This report addresses these issues. Key Topics Covered: 1. Introduction Report Objectives Methodology and Sources Statistical Notes 2. Antibiotics Overview Bacteria Taxonomy Microbes in Context Antibiotics Definition Quest for Super Drugs Soil Microbes Antibiotic Categories Gram-Positive vs. Gram-Negative Bacteria Static vs. Cidal Susceptibility, Potency and MIC Bactericidal Antibiotics Breakpoint Efficacy and Safety Mechanisms of Action Antibiotic Resistance Resistance Is Nothing New Costs of Antibiotic Resistance Treatment Guidelines Antibiotic Overuse ESKAPE Most Common Infections Antibiotic Resistance Prevention National Action Plan for Combating Antibiotic Resistant Bacteria BARDA and NIAID Budgets Presidential Advisory Council United Kingdom Review on Antimicrobial Resistance Margolis Center for Health Policy GAIN Act 21st Century Cures Act MRSA on the Decline CRE Poses an Urgent Threat Failure Rate High Global Problem U.S. Cases Carbapenems Use Increasing ESBLs Pose a Serious Threat New Delhi Metallo-Beta-Lactamase Clostridium difficile Few New Antibiotics Being Produced Low NPV Cost of Trials New Antibiotics Hard to Discover iChip Five Pharma Companies Left Development Now Done by Startups Numerous Studies on Situation Disaster Planning Path Forward Alternative Is Unimaginable 3. Quest For Super Antibiotic Drugs Discovery Platform Has Collapsed New Antibiotic Discovery Process Rationally Improve Existing Antibiotics Rediscover Old Antibiotics Repurpose Old Drugs Discover Untested New Chemical Diversity Community for Open Antimicrobial Drug Discovery Target-Based Approaches Long Time-Lower Success Rates Focus for New Antibiotic Drugs Well Established Dearth of New Antibiotic Drug Classes R&D Development and Commercial Challenges Modest Performance of New Antibiotics Few Big Players Remain New Key Initiatives Growing Wave of Activity in Antibiotics Activity Mostly Led by Biotechs Renewed Enthusiasm Antibiotics in Late Clinical Development Obtaining Investments for New Antibiotics Is Difficult Startups Believe They Can Find New Antibiotics Antibiotics Approved in Recent Years Stewardship New Antibiotics That Have Received Marketing Authorization Disappointing Sales Post-Launch Generic Competition Beta-lactamases, Cephalosporinase and Carbapenemase Inhibitors New Cephalosporins New Aminoglycosides New Pleuromutilins New Tetracyclines New Macrolides New Fluoroquinolones and DNA Gyrase Inhibitors New Oxazolidinones New Fatty Acid Biosynthesis Inhibitors New Folate Biosynthesis Inhibitors Defensin-Mimetic Peptides Other Classes Old Antibiotics with New Dosing Ramoplanin Fusidane Fosfomycin Early-Stage Molecules Analogs of Existing Classes Still Difficult to Develop New Oral Antibiotics for Outpatients Urgently Needed New Oral Antibiotics for Children Urgently Needed Government Incentives Needed Options Market for Antibiotics Antibiotics Prize 4. Antibiotics Market Antibiotics Production Value Production Value by Class Quinolones Cephalosporins Marcolides Penicillins Carbapenems Tetracyclines Sulfonamides Aminoglycosides Other Antibiotics Production by Region Consumption Volume Data Antibiotic Market Volume Consumption by Country Class Differences by Country Inappropriate Use Public Health Issues Applications Anti-MRSA Antibiotics Cubicin Zyvox Teflaro Tygacil Vibativ Dalvance Other Community Acquired Bacterial Pneumonia Healthcare-Associated Infections Decreasing Medicare Part D Competitive Environment Large Pharma Exits Antibiotics Biotech Enters Antibiotics Antibiotic Deal Making Competitors Market Shares Antibiotic Supply Chains India and China Antibiotic Supply Chains Antibiotic Pollution Issues Chinese Companies North China Pharmaceutical Group CSPC Pharmaceutical Group/Inner Mongolia Changsheng Pharmaceuticals Sinopharm WeiQida Shandong Lukang Pharmaceuticals Harbin Pharmaceutical Group Tonglian Group United Laboratories Indian Companies Aurobindo Mylan Laboratories Ltd. Dr Reddy's Hetero Drugs Ltd. Orchid Pharmaceuticals 5. Company Profiles Appendix 1: Antibiotic Classes Aminoglycosides ß-Lactams ß-Lactam Resistance Penicillins Carbapenems Cephalosporins Fluoroquinolones Lipoglycopeptides Lipopeptides Oxazolidinones Macrolides Tetracyclines Appendix 2: Regulation Food, Drug, and Cosmetic Act Approval Process Preclinical Studies Clinical Trials Marketing Approval Foreign Clinical Trials Approval Letter Special FDA Expedited Review and Approval Programs Breakthrough Therapy Post-Approval Requirements Section 505(b)(2) Qualified Infectious Disease Product Exclusivity Companies Mentioned - Achaogen Inc - Actelion Ltd. - AstaZeneca plc - Atox Bio - Basilea Pharmaceutica AG - Cempra Inc - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - Destiny Pharma Ltd. - Dong Wha Pharmaceuticals - Durata Therapeutics, Inc. - Eisai Co., Ltd. - Furiex Pharmaceuticals, Inc. - GlaxoSmithKline, Plc. - Grupo Ferrer Internacional S.A. - Insmed Incorporated - KaloBios Pharmaceuticals, Inc. - Melinta Therapeutics, Inc. - Merck & Co., Inc - MerLion Pharmaceuticals Pte Ltd - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - Novartis AG - Osel Inc - Otonomy, Inc - Otsuka Pharmaceutical Co. Ltd. - Paratek Pharmaceuticals, Inc. - Pfizer Inc - Polyphor Ltd. - Rebiotix, Inc - Roche Holding AG - Savara Pharmaceuticals - Sequella, Incorporated - Seres Therapeutics, Inc. - Summit, plc - TaiGen Biotechnology Co., Ltd. - Tetraphase Pharmaceuticals, Inc - The Medicines Company - Theravance Biopharma Inc For more information about this report visit https://www.researchandmarkets.com/research/8...iotics_the
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
